Accera

Pharmasri—We can provide Company reports, each will be only US$10 only.
www.pharmasri.com
Please contact us at mailto:info@pharmasri.com
Accera, Inc.
COMPANY GENERAL
Address Interlocken Advanced Technology Park

380 Interlocken Crescent
Suite 780
Broomfield, Colorado 80021
TEL 303.999.3700
FAX 303.999.3799
Country U.S.A
Industry Biotechnolgy
Type Private
Therapeutic are Neurology
Web www.accerapharma.com
subsidiary Neuera Pharmaceuticals, Inc.
Highest Phase Phase II
President and CEO Steve Orndorff, Ph.D.

Contact sorndorff@accerapharma.com
Partenering details Accera is currently seeking partners to commercialize

Axona outside the United States.
Seeking business relationships that are collaborative and

allow Accera to participate in both clinical development
and commercialization of partnered product candidates.
Partnering Contat Eric Schauble mail:eschauble@accerapharma.com

1-303-999-3718
PIPELINE ANALYSIS
www.pharmasri.com
Trad
Route of
Drug e Synon Trial
Summary Ingredient Indication administr Other
Name↑ Nam ym Phase
ation
e
Axona is alo
s being
developed
Ketasin ( for Memory Axon Caprylictrigl Phase Memory
- - -
Axona) Impairment a yceride II Impairment
and is in
preclinical
trials.
Axona Axona is a Axon Caprylic - Market Dietary POWDER PRESCRBIN
prescription- a triglyceride ed Suppliment GINFO
only medical in mild-to-
food moderate AD
intended for
the clinical
dietary
managemen
t of the
metabolic
processes
associated
with mild-to-
moderate
Alzheimer's
disease. In
clinical
trials, Axona
has been
shown to
safely
improve
cognitive
function and
memory in
AD patients.
Axona
addresses
the
hypometabol
www.pharmasri.com
Trad
Route of
Drug e Synon Trial
ation
e
ism or
defective
metabolism
of glucose
that occurs
in those
areas of the
brain that
are involved
in
Alzheimer’s
disease.
Accera
engages in
research,
development
and
commerciali
zation of
other clinical
applications
for Axona.
A non
selective
inhibitor of
both isoform
s of acetyl- Preclini
Parkinson,s
AC-8632 coenzyme - - - cal - -
disease
Acarboxylas Drug
e that plays
a key role in
fatty acid
synthesis
ketogenic ag Ketasy Phase Parkinson,s
AC-1202 - - - -
ent n II disease
AC-0523 New - - - Preclini Huntigton,s - -
chemical cal disease
entity, which Drug
www.pharmasri.com
Trad
Route of
Drug e Synon Trial
ation
e
addresses
mitochondri
al
dysfunction
CLINICAL TRIALS
Study StudyFirstReceive
Status↑ Study Phase Drug Lastupdated
startdate d
Ketasyn in Mild to
Complete Phase Ketasyn
Moderate Alzheimer's 1-Sep-05 30-Dec-08
d II (AC-1202)
Disease
Ketasyn In Age-
Complete Phase
Associated Memory Ketasyn 1-Sep-05 30-Dec-08
d II
Impairment
Safety of Three
Formulations
Complete
of KetasynAdministere Phase I Ketasyn 1-Sep-05 30-Dec-08
d
d for 14 Days in
Healthy Elderly
FINANCIAL INFO
Date
Title
Announced
Accera announced the culmination of its "Lost & Found" campaign, an online
educational initiative whereby each visit to www.lostandfoundcampaign.com
prompted a donation by Accera to support the Alzheimer's Foundation of America
(AFA).
17-Nov-09
All funds generated through this initiative, which totaled $25,000, are being
donated to AFA today for "National Memory Screening Day" to further the
organization's efforts to support individuals with Alzheimer's disease and their
families.
11-Nov-08 Accera has recently closed a Series C financing round of $35 million (€ 27
www.pharmasri.com
Date
Title
Announced
million), led by Inventages Venture Capital SA. Proceeds of this financing will be
used to begin sales and marketing of the company’s lead product, Axona™
(previously known as Ketasyn), which is scheduled to launch in the United States
in the first quarter of 2009.
Inventages was joined in this round by San Diego-based POSCO BioVentures and
other previous private investors. Inventages and POSCO participated in the
Company’s Series A and B rounds.
Accera has recently closed a Series B financing round of $7.5 million led by
16-Aug-06
Inventages Venture Capital SA.
Accera has recently closed a Series A financing round of $6 million. The financing
16-Sep-04 was led by inventages Venture Capital GmbH of Geneva, Switzerland and joined
by San Diego-based POSCO BioVentures.
NEWS ANALYSIS
Date
Type Summary
Realeases
3/9/2010 Clinical Study New Evidence Further Validates Ketone Body Therapy as an
Effective Approach in Managing Alzheimer's Disease
Accera announced data which showed that augmentation with
ketone bodies significantly improved cognitive function in
Alzheimer's disease (AD) patients.
An early feature of AD is region specific declines in cerebral
glucose metabolism. One strategy has been to supplement the
brain's normal glucose supply with ketone bodies. The company's
data was drawn from two clinical studies which examined the
cognitive effects of induced ketosis. In both acute and chronic
dosing, AC-1202 (Axona®) significantly induced ketosis two hours
after administration. Further analysis of the studies revealed that
patients administered Axona who lacked the epsilon 4 variant of
the APOE gene (E4(-)), demonstrated significant improvement
from baseline values in the Alzheimer’s Disease Assessment
Scale-Cognitive (ADAS-Cog) and improvement compared to
placebo. In the population of patients who were both APOE4(-)
and dosage compliant, more pronounced improvements in ADAS-
cog scores were observed at each assessment timepoint (Day 45
and Day 90). At Day 45 the improvement in ADAS-cog score
relative to Placebo was 6.26 (p=0.001), while at Day 90 the
difference was 5.33 (p=0.006). These improvements were
www.pharmasri.com
Date
Type Summary
Realeases
remarkable in that they were seen in patients who were already
taking prescription Alzheimer medications. Many clinicians
consider an improvement greater than 4 points to be clinically
significant. http://www.adi2010.org/default.aspx?
pageid=Abstracts
Accera, Inc. to Present at the 3rd Annual European Life Science
CEO Forum for Partnering & Investing
2/1/2010 General Accera will present at the 3rd Annual European Life Science CEO
Forum for Partnering & Investing February 11-12, 2010 at the
ConventionPoint in Zurich, Switzerland.
Tips for Caregivers and a New Therapy Offers Hope in the Fight
Against Alzheimer’s
November is Alzheimer’s Awareness Month. Every 70 seconds
someone in the United States develops Alzheime’s disease, and
the number of cases is expected to double every 20 years. This
devastating and progressive disease not only affects patients, but
also takes a physical toll on the friends and family members who
care for them. Caring for a family member or friend with
Alzheimer’s can be a full time job. If you are caring for someone
with Alzheimer’s, you are not alone—almost 10 million Americans
provide unpaid care for a person with Alzheimer’s disease or other
dementias. In addition to the financial burden this places on
friends and family, caregivers often experience profound
11/23/2009 General emotional changes such as feelings of loss and grief.
While there is no cure for Alzheimer’s, there are drugs and
medications that target the symptoms. If you or a loved one is
experiencing symptoms of memory loss and disorientation, talk
with your physician about different therapy options. One of the
newest prescription therapies, Axona® provides the brain with an
alternative source of energy. In Alzheimer's patients, brain cells
often do not efficiently use glucose, a main fuel for the brain, and
as a result the cells do not function properly. Axona works by
getting into the cell through other pathways and provides the cell
the fuel it needs to continue functioning. Available on the market
since March 2009, Axona has been clinically shown to improve
cognitive function and memory and is now showing positive
results in Alzheimer’s patients.
11/17/2009 Charity Accera, Inc. Announces Culmination of Lost & Found Campaign:
Company Donates $25,000 to the Alzheimer's Foundation of
America for National Memory Screening Day
www.pharmasri.com
Date
Type Summary
Realeases
Accera announced the culmination of its "Lost & Found" campaign,
an online educational initiative whereby each visit to
www.lostandfoundcampaign.com prompted a donation by Accera
to support the Alzheimer's Foundation of America (AFA).
Accera, Inc. to Present at Lazard Capital Markets 6th Annual
Healthcare Conference
Accera will present at Lazard Capital Markets 6th Annual
Healthcare Conference November 17-18, 2009 at the St. Regis
11/11/2009 Conference Hotel in New York. Steve Orndorff, Ph.D., founder, president and
CEO, will provide a corporate overview of Accera and an update
on Axona™ on Tuesday, November 17 at 4:10 p.m. EST. A
breakout session will follow Dr. Orndorff’s presentation where he
will be available for questions and answers
Accera, Inc. Awarded “Company of the Year” by the Colorado
BioScience Association
11/11/2009 Award
Accera has been elected as The Colorado Bioscience Association's
2009 “Company of the Year” Award recipient.
Accera Inc. to Present at UBS Global Life Sciences Conference
9/18/2009 Conference Accera will present at the UBS Global Life Sciences Conference
September 21-23, 2009 in New York.
8/12/2009 Clinical Results Accera Announces Peer-Reviewed Publication of the Results of its
90-day Clinical Study of AC-1202 (Axona™) in Mild to Moderate
Alzheimer’s Disease
Accera announced the publication of a scientific paper in the peer-
reviewed journal Nutrition & Metabolism. The paper, entitled
“Study of the ketogenic agent AC-1202 in mild to moderate
Alzheimer’s disease: a randomized, double-blind, placebo-
controlled, multicenter trial” suggests that daily administration of
AC-1202 (Axona™) can help improve cognition and memory in
patients with mild-to-moderate Alzheimer’s disease (AD).
The 90-day, randomized, double-blind, placebo-controlled,
parallel-group study, evaluated the effect of daily dosing of AC-
1202 in patients diagnosed with mild-to-moderate Alzheimer’s
disease. The study was conducted in 152 patients at 23 clinical
sites throughout the United States. The study examined the
effects of AC-1202 on performance in the Alzheimer’s Disease
Assessment Scale – Cognitive subscale (ADAS-Cog). Notably,
participants in the study were allowed to remain on their current
Alzheimer’s disease medications and did not have to alter their
diets in any way. Approximately 80% of the participants were
www.pharmasri.com
Date
Type Summary
Realeases
taking one or more Alzheimer’s disease drugs.
Researchers found that AC-1202 was safe and produced a
beneficial trend for the overall subject population and significant
cognitive benefits in a predefined analysis of patients who did not
carry the epsilon 4 (E4) variant of the apolipoprotein E gene
(APOE4). Possession of an APOE4 allele is the major genetic risk
factor for development of the most common form of Alzheimer’s
disease. In addition, there was a significant correlation between
improvement in cognition and memory and amount of AC-1202
consumed by APOE4(-) patients, i.e., dosing compliance. This
finding suggests that AC-1202 may offer a novel and effective
genotype-specific strategy for Alzheimer’s disease. Approximately
50% of the general Alzheimer’s disease patient population is
APOE4(-).
Accera, Inc. to Support the Alzheimer’s Foundation of America’s
National Memory Screening Day through On-line Awareness
Effort.
Accera, Inc., a biotechnology company delivering breakthrough
8/11/2009 Charity therapies in central nervous system diseases, announced today
the launch of its “Lost & Found” campaign, an on-line initiative
whereby each visit towww.lostandfoundcampaign.com prompts a
$1 donation by Accera to support the Alzheimer’s Foundation of
America (AFA).
Accera, Inc. Announces Dr. Gunnar Weikert Elected to Board of
Directors
Accera announced that Gunnar Weikert, M.D., Ph.D., has been
elected to its board of directors. Dr. Weikert is the Chairman, CEO
and Founder of Inventages Venture Capital. Prior to the founding
of Inventages, he had more than 10 years experience in a broad
7/27/2009 Management
spectrum of executive functions in the pharmaceutical industry
culminating as senior vice president and global head for life
sciences transactions at Bayer AG. While at Bayer, he oversaw
venture investments in technology companies and collaborations
representing some of the largest transactions involving large
pharmaceutical and biotechnology companies in the late 1990s.
7/14/2009 Product Related Evidence for a New Genetic Link to Therapeutic Efficacy for
Alzheimer’s Disease
Accera announced further evidence for genetic interactions
impacting the efficacy of the ketogenic compound AC-1202
(Axona™) in Alzheimer’s disease. New data from the company’s
www.pharmasri.com
Date
Type Summary
Realeases
previously completed double-blind, placebo-controlled trial in
patients with mild-to-moderate Alzheimer’s disease demonstrates
an interaction between two genetic markers that strongly
influence the therapeutic response in patients. Dr. Samuel
Henderson, Executive Director of Research, will present these
results at the 2009 International Conference on Alzheimer’s
Disease (ICAD) sponsored by the Alzheimer’s Association.
During this study, patients received daily administration of either
AC-1202 or placebo for 90 days, with efficacy assessments
performed at Baseline (Day 0), Day 45, Day 90 and after a two
week washout from their assigned product on Day 104. In
addition, analyses of a number of genotypic markers judged to be
relevant to the physiological background of Alzheimer’s disease
were also performed.
Previous analysis of the study revealed that patients administered
AC-1202 who lacked the epsilon 4 variant of the APOE gene
(E4(-)), demonstrated significant improvement from baseline
values in the Alzheimer’s Disease Assessment Scale-Cognitive
(ADAS-Cog) and improvement compared to placebo of 4.77 at
Day 45 and 3.36 at Day 90 (p < 0.05). ADAS-Cog, a
neuropsychometric battery of tests that measures short-term
memory and cognition, is probably the most widely used cognitive
instrument used in clinical trials of anti-dementia drugs within the
United States and Europe. Numerous clinical studies have
demonstrated that modest improvements in ADAS-cog scores –
on the order of 2 to 3 points over the course of a year – have
been associated with significant cost reductions in overall
managed care expenditures.
To further investigate pharmacogenomic responses of AC-1202 in
AD, the effects of APOE4 carriage status and a polymorphism
(IDE_7) in the insulin degrading enzyme gene (IDE) on ADAS-Cog
scores were evaluated over the study course. In addition to
degrading insulin, the IDE protein also degrades amyloid beta
peptide and has been implicated in playing a role in Alzheimer’s
disease.
In the population of patients who were both APOE4(-) and lacked
the C/C polymorphism in IDE 7, more pronounced improvements
in ADAS-cog scores than those previously reported were observed
at each assessment timepoint (Day 45, 90 and 104). At Day 45
the improvement in ADAS-cog score was 4.18 (p=0.0004), while
www.pharmasri.com
Date
Type Summary
Realeases
at Day 90 the difference was 4.73 (p=0.001). Of interest, a
significant difference in cognitive test scores of 3.27 was observed
two weeks after termination of AC-1202 treatment (p=0.034).
This finding suggests that daily administration of AC-1202 may
produce lasting effects in those patients with this combination of
genotypic markers.
The combination of the E4(-); IDE_7(C/C)(-) genotype is
prevalent in approximately 40% of the AD population, so the
number of potential responder patients is substantial.
Accera, Inc. Launches Neuera Pharmaceuticals, Inc.
Accera, Inc., a biotechnology company delivering breakthrough
therapies in central nervous system (CNS) diseases, announced
today the formation of Neuera Pharmaceuticals, Inc., a drug
development company. The new company will focus on the
discovery and development of proprietary small molecule drugs
for acute and chronic neurological conditions where the
mechanism of defective energy metabolism or hypometabolism is
involved.
Neuera Pharmaceuticals will operate as a wholly owned subsidiary
Forming a
4/15/2009 and will be spun out of Accera as a stand-alone company after the
subsidiary
completion of a $12 million series A financing round. Existing
Accera investors have already committed to participate in the
capital raise. Some of Accera’s management and staff will join the
newly formed company, and the current small molecule pipeline
at Accera including the preclinical compounds, AC-0523 and AC-
8632, have been transferred to Neuera. In addition to in-house
development of small molecules, Neuera Pharmaceuticals is
actively pursuing the license or acquisition of late clinical-stage
products for CNS diseases or conditions that complement the
hypometabolism platform.
Accera, Inc. to Present at Upcoming Investor Conferences
3/25/2009 Conference Accera announced that the company will be participating at two
upcoming healthcare investor conferences.
3/24/2009 Management Dr. Thomas Werner Elected to Accera, Inc.’s Board of Directors
Accera announced that Thomas Werner, Ph.D. has been elected to
its board of directors. Since 2001, Dr. Werner has been a
managing director and senior vice president of GlaxoSmithKline
(GSK) and has served as CEO of the GSK Foundation until earlier
this year. He led the Pharmaceutical Research Manufacturers of
America (PhRMA) in Germany as its chairman through November
www.pharmasri.com
Date
Type Summary
Realeases
2008. He began his pharmaceutical career with Squibb Pharma
Germany where he held sales, marketing and brand management
positions from 1983-1989 and later held executive management
positions at Bristol-Myers Squibb. Dr. Werner earned his Ph.D. in
chemistry at the University of Göttingen in Germany.
Accera Launches Axona™, First Medical Food Therapy to Help
Manage Mild-to-Moderate Alzheimer’s Disease
Accera launched AxonaTM in the United States for Alzheimer’s
disease (AD). Axona is a first-in-class medical food for the clinical
3/2/2009 Product Launch
dietary management of the metabolic processes associated with
mild-to-moderate Alzheimer’s. Dispensed by prescription, it
targets the metabolic deficiencies and imbalances associated with
AD by providing an alternative energy source for brain cells.
Accera, Inc. Sponsors Alzheimer’s Association’s 2009 ICAD
Conference
Accera announced that it is a SILVER level sponsor of the 2009
2/19/2009 Conference International Conference on Alzheimer’s Disease (ICAD). The
annual conference, put on by the Alzheimer’s Association, is the
world’s leading forum on dementia research. ICAD 2009 will take
place July 11-16 in Vienna, Austria.
Accera Will Launch Axona, New Approach to Managing Alzheimer’s
Disease, in 2009
Accera will launch AxonaTM in the United States for Alzheimer’s
11/18/2008 Product News
disease (AD) in the first quarter of 2009. The commercial launch
of Axona will be funded by the company’s recent Series C equity
financing.
Accera, Inc. Completes $35 Million Series C Financing
Accera has recently closed a Series C financing round of $35
million (€ 27 million), led by Inventages Venture Capital SA.
11/11/2008 Finance Proceeds of this financing will be used to begin sales and
marketing of the company’s lead product, Axona™ (previously
known as Ketasyn), which is scheduled to launch in the United
States in the first quarter of 2009.
Accera, Inc. to Present at BIO CEO & Investor Conference
Accera announced that Dr. Steve Orndorff, Accera’s president and
2/7/2008 Conference CEO, will be presenting at the BIO CEO & Investor Conference on
February 12 at 3:30 p.m. EST at the Waldorf-Astoria in New York
City.
11/2/2007 Conference Accera, Inc. to Present at Rodman & Renshaw 9th Annual
Healthcare Conference
www.pharmasri.com
Date
Type Summary
Realeases
Accera Inc. announced today that the company will be
participating in the Rodman & Renshaw 9th Annual Healthcare
Conference November 5-7 at the Palace Hotel in New York City.
President and CEO Dr. Steve Orndorff will present the company
November 7 at 12:40 p.m. in the Hubbard Room.
William Poncy Appointed as Vice President, Commercial
Development
Accera, Inc. has appointed William T. Poncy, M.B.A., as Vice
President of Commercial Development. He will direct the
commercial launch of Ketasyn (AC-1202) as a medical food
product in the U.S. for the treatment of Alzheimers' disease and
the development of the ethical drug franchise for
neurodegenerative diseases at Accera.
Accera, Inc. to Present at the 4th Annual BIO Investor Forum
Accera Inc., a privately held biotechnology company focused on
developing novel drugs for neurodegenerative diseases,
10/4/2007 Conference
announced today that the company will be participating in the 4th
Annual BIO Investor Forum next week at the Palace Hotel in San
Francisco
Ketasyn Improves Memory in Age-Associated Memory Impairment
Study
A double-blind, placebo-controlled Phase II study with 159
subjects characterized with Age-Associated Memory Impairment
showed that Ketasyn (AC-1202) has a positive and clinically
8/29/2007 Product news
meaningful effect on memory in older adults. The study results
were consistent with earlier Phase II studies done with
Alzheimer's disease patients, particularly those with the APOE4(-)
genotype who showed significant improvement in memory and
cognition.
Experimental Drug Ketasyn (AC-1202) Treats Alzheimer's as
Diabetes of the Brain
Accera, Inc. announced today that recent data from its Phase IIb
6/26/2007 Product news
study in Alzheimer's disease (AD) support findings showing that
AD may effectively be thought of and treated as diabetes of the
brain.
6/11/2007 Clinical results Accera, Inc. Announces Open-Label Data from Phase II Study in
Alzheimer's Disease at International Conference on Prevention of
Dementia
All subjects who were treated with AC-1202 during the full nine
months of the double-blinded and open-label phases of the clinical
www.pharmasri.com
Date
Type Summary
Realeases
trial showed very little disease progression. Patients with the
ApoE4(-) genotype who started taking AC-1202 for the first time
during the open-label extension showed significant improvement
in memory and cognition. This result was consistent with the
double-blinded phase of this study as well as an earlier Phase IIa
clinical study.
Accera, Inc. to Present at Upcoming Investor Conferences
Accera, Inc. announced today that the company will participate in
three upcoming healthcare investor conferences, Dr. Steve
5/8/2007 Conference Orndorff, President and CEO, will make presentations about the
business of the company, its technology platform and the recent
positive data from a Phase IIb study of AC-1202 for Alzheimer's
disease.
Accera announced the line results of a Phase IIb clinical study of
its lead compound, AC-1202, in 152 patients diagnosed with mild-
to-moderate Alzheimer's disease. The multi-center trial,
conducted in the U.S., was designed as a double-blinded, placebo-
5/4/2007 Clinical Results controlled study over 104 days, followed by a six month open-
label extension phase. Signficant efficacy was observed in those
patients treated with AC-1202, particularly in those with the
ApoE4(-) genotype and one other pharmacogenomic marker that
is involved in brain energy metabolism.
Accera Presents Phase IIb Clinical Data at American Academy of
Neurology
Accera announced today that the line data from its Phase IIb
4/24/2007 Presentation study of its lead compound, AC-1202, in Alzheimer's disease will
be presented at the annual meeting of the American Academy of
Neurology in Boston by Dr. Lauren Costantini, Vice President of
Clinical Development.
Accera Participates in Neurotechnology Industry Organization
Public Policy Tour
Accera executive management participated in a public policy tour
with the Neurotechnology Industry Organization (NIO) that met
with the FDA, NIH and elected members of Congress to discuss
4/3/2007 Conference opportunities and obstacles facing companies in the development
of new therapies for diseases of the central nervous system.
During the tour NIO promoted the concept of a National
Neurotechnology Initiative with a federal National Coordination
Office to direct existing multi-agency efforts in neurotechnology.
Accera is a founding member of NIO.
www.pharmasri.com
Date
Type Summary
Realeases
Accera Enters Product Development Agreement with Nestle Purina
PetCare
Accera, Inc. announced today an agreement under which it has
1/8/2007 Deals&alliance
granted Nestle Purina PetCare Global Resources, Inc. the right to
develop its proprietary compound, AC-1203, for application to
healthy aging and wellness in dogs and other companion animals.
Accera Initiates Phase 2 Trial in Age Associated Memory
Impairment
Accera, Inc., a drug development company focused on Alzheimer's
8/8/2006 Clinical trial disease and related neurodegenerative diseases, announced it has
initiated a multi-center, placebo-controlled Phase IIa study of
KetasynTM (AC-1202) for the treatment of Age Associated
Memory Impairment (AAMI).
Accera Completes $ 7.5 Million Series B Financing
Accera, Inc., a drug development company focused on Alzheimer's
8/16/2006 Finance disease and related neurodegenerative diseases, announced it has
recently closed a Series B financing round of $7.5 million led by
Inventages Venture Capital SA.
Accera Names Lauren C. Costantini, Ph.D., as Vice President,
Clinical Development
Accera announced today the appointment of Lauren C. Costantini,
Ph.D., as Vice President of Clinical Development. She has a
distinguished career in neuroscience with experience in all phases
11/3/2006 Management of clinical development from research to Phase III clinical trials for
therapeutic products ranging from chronic pain and opioid
dependency to spinal cord injury and Parkinson's disease. Most
recently she was Director of Product Development at Titan
Pharmaceuticals and previously was on the faculty at Harvard
Medical School.
Accera Researchers Demonstrate That a Low-Carbohydrate, High-
Fat DIet Reduced Markers of Alzheimer's Disease in a Transgenic
Mouse Model
10/17/2005 Research Accera announced that company researchers have demonstrated
that an extremely low-carbohydrate, high-fat diet, known as a
"ketogenic diet" reduced levels of the amyloid beta peptide in a
transgenic mouse model of Alzheimer's disease (AD).
9/8/2005 Product News Accera Expands Ongoing KetasynTM Clinical Trial for Alzheimer's
Disease
Accera, Inc. announced today that it has received approval to
provide Alzheimer's disease patients in its' ongoing Phase IIb
www.pharmasri.com
Date
Type Summary
Realeases
clinical trial the opportunity to receive KetasynTM (AC-1202)
treatment in a formal open label six-month extension study.
Accera Establishes Clinical and Scientific Advisory Boards for Its
Pioneering Approach to Alzheimer's Disease
Accera announced the formation of a Clinical Advisory Board
(CAB) and Scientific Advisory Board (SAB) to assist in the
12/14/2004 General
Company's product development efforts. Accera is developing a
new class of therapeutic products to treat or prevent Alzheimer's
disease (AD) and related neurodegenerative diseases that are
often associated with aging.
Accera Names Gary Hooper as Board Member
Accera announced the appointment of Gary Hooper to its Board of
12/9/2004 Management Directors. Mr. Hooper has nearly twenty years of executive
management level experience in the biotechnology industry and
broad experience in corporate and business development.
Claude H. Nash Joins Accera, Inc. as Chairman of the Board
Accera announced the appointment of Claude H. Nash, Ph.D. to
Chairman of the Board. Dr. Nash has been a leading figure in the
biotechnology industry as President of ViroPharma, Inc. He brings
to Accera more than 20 years of executive management
experience in the pharmaceutical and biotechnology industries.
Accera Completes $6 Million Series A Financing
Accera has recently closed a Series A financing round of $6
9/16/2004 Finance million. The financing was led by inventages Venture Capital
GmbH of Geneva, Switzerland and joined by San Diego-based
POSCO BioVentures.
MANAGEMENT
Name Position mail Summary

Steve A. Founder, mail: Steve Orndorff is a serial
Orndorff, Ph.D. President and sorndorff@accerapharma.com entrepreneur with more than
Chief Executive 25 years experience in the
Officer biotechnology industry.
Previously he was President
and CEO of Univera
Pharmaceuticals, Inc., a drug
discovery company focused on
diseases of inflammation and
www.pharmasri.com
the immune response. During
his career he has had
responsibility in a broad array
of disciplines such as basic
research, manufacturing,
product development and
business development at
various biotechnology
companies including Genex
Corporation, NutraSweet, Inc.,
and ZeaGen, Inc. Dr. Orndorff
is a past President of the
Society for Industrial
Microbiology and a founding
Board member of the Colorado
BioScience Association. He
received a B.S. in Biology from
Virginia Tech and a Ph.D. in
microbiology from University of
Maryland.
William T. Vice President, William brings more than 25
Poncy, M.B.A. Commercial years of experience in the
Development pharmaceutical industry to
Accera. He has a demonstrated
track record of success in all
aspects of the pharmaceutical
commercial organization. Prior
to joining Accera in 2007, he
was Vice President of Sales and
Marketing for Myogen, Inc.
(acquired by Gilead Sciences)
where he built the commercial
organization and launched a
pulmonary anti-hypertension
franchise. Previously he was
Vice President of Sales and
Marketing, North America for
Pharmion where he developed
an oncology commercial
organization. He started his
career in field sales with Berlex
www.pharmasri.com
Labs and then from 1982 until
2000, William held several
positions at DuPont
Pharmaceuticals including
sales, managed care, trade,
marketing, public policy and
various management roles. Bill
received his B.S. in Biological
Science from the University of
California, Irvine and his M.B.A.
from the University of Phoenix.
Samuel Henderson's research
has defined new pathways in
the understanding of
neurodegenerative diseases,
such as Alzheimer's disease.
Most recently, Dr. Henderson
was at The Institute of
Behavioral Genetics, University
of Colorado, Boulder, CO where
he investigated the genetics of
aging. Prior to that, he was a
Lead Scientist at GenoPlex, Inc.
directing research in anti-aging
technologies. Dr. Henderson
Samuel Vice President,
has co-authored numerous
Henderson, Research &
scientific publications, patents
Ph.D. Development
and reviews, including
fundamental discoveries in
aging research. He received his
B.A. in Biology from
Washington University, St.
Louis, MO and his Ph.D. in
Molecular Genetics and Cell
Biology from University of
Chicago. He received extensive
post-doctoral training in
developmental biology at the
University of Wisconsin. Dr.
Henderson is the scientific
founder of Accera.
www.pharmasri.com
Gregory Kading has over 20
years experience in finance and
accounting in a variety of
positions with US West (now
Qwest Communications),
including accounting
operations, financial planning
and analysis, financial
modeling, business planning
and corporate investment
analysis. Most recently he was
Director of Finance for the
Broadband Services unit of
Gregory
Vice President, Qwest. He has been a financial
Kading, CFA,
Finance consultant for numerous start-
M.B.A.
up companies and has been an
adjunct instructor at Metro
State College of Denver and
Arapahoe Community College.
Greg was awarded the
Chartered Financial Analyst
designation from the CFA
Institute. An Iowa native, Greg
holds a B.S. in Industrial
Engineering from Iowa State
University, and an M.B.A.
degree from Creighton
University.
Claude H. Nash, Chairman Dr. Nash brings to Accera more
Ph.D. than 20 years of executive
management experience in the
pharmaceutical and
biotechnology industries.
Claude Nash is currently the
President and CEO of
Bloodstone Ventures plc.
Previously he was the founder,
CEO, and chairman of
ViroPharma Inc. where he
oversaw the development of
several antiviral drugs,
www.pharmasri.com
successfully raised $430M in
capital and achieved a $1.2B
market capitalization for the
company following its Initial
Public Offering. Prior to
founding ViroPharma, Dr. Nash
was Vice President of infectious
disease and cancer research at
the Schering-Plough Research
Institute where he initiated
new strategic technologies for
drug discovery and advanced
three new drugs into
development. Throughout his
career he has managed the
research and development of
more than twenty drugs in the
areas of infectious diseases,
cancer, hypertension and pain.
In the past he worked for
several large pharmaceutical
companies including Sterling-
Winthrop, Smith Kline &
French, and Eli Lilly. He is
currently a director of Adolor,
Inc. Dr. Nash earned his Ph.D.
degree in microbial genetics
and biochemistry from
Colorado State University.
Gary Hooper Director Mr. Hooper has nearly twenty
years of executive
management level experience
in the biotechnology industry
and broad experience in
corporate and business
development. Gary was
recently Vice President of
Business Development for
Bioproducts at Genencor
International. He previously
served as President and CEO of
www.pharmasri.com
Ciblex Corporation, a biotech
company developing
therapeutic drugs for
inflammatory diseases through
inhibition of cell-to-cell
communication. He has held a
number of executive and senior
management positions at
Cygnus Therapeutic Systems,
Genentech and Baxter
Travenol. Gary is on the Board
of Directors for the University
of Southern California,
Scientific Advisory Council at
the University of Utah, Board of
Directors of Joint Venture:
Silicon Valley Network, Board
of Trustees for the Licensing
Executives Society and
executive member of the
Health Care Committee, and
Chairman of Silicon Valley's
Technology Convergence
Consortium. He received an
M.B.A. degree in management
from the University of Southern
California.
Steve A. Director Dr. Orndorff is the founder,
Orndorff, Ph.D. President and CEO of Accera,
Inc. He has more than 25 years
experience in the biotechnology
industry. Previously he was
President and CEO of Univera
Pharmaceuticals, Inc., a
privately-held drug discovery
company focused on diseases
of inflammation and the
immune response. During his
career he has had responsibility
in a broad array of disciplines
such as basic research,
www.pharmasri.com
manufacturing, product
development and business
development at various
biotechnology companies
including Genex Corporation,
NutraSweet, Inc., and ZeaGen,
Inc. Dr. Orndorff is a past
President of the Society for
Industrial Microbiology and a
founding board member of the
Colorado BioScience
Association. He received a
Ph.D. in microbiology from the
University of Maryland.
Wolfgang Director Dr. Reichenberger has many
Reichenberger, years of financial and executive
Ph.D. management experience in the
food and nutrition industry.
During a 29 year career at the
world's largest food company,
Nestle SA, he led different
functions and overall
operations in Europe, Asia,
Oceania, and North and South
America. Recently he was
Executive Vice President and
Chief Financial Officer of Nestle
SA, and he served on the
governing admission body at
the Swiss Stock Exchange.
Currently he is Founder and
General Partner of Inventages
WHealth Management Inc. and
IVC Americas SA. Dr.
Reichenberger serves on the
Board of Directors for several
U.S. and European
biotechnology companies. He
earned a Masters of Business
Administration from Hochschule
St. Gallen and a Ph.D. in
www.pharmasri.com
Business Administration from
Wirtschaftsuniversitaet Wien.
Dr. Weikert is the Chairman,
CEO and Founder of Inventages
Venture Capital. Prior to the
founding of Inventages, he had
more than 10 years experience
in a broad spectrum of
executive functions in the
pharmaceutical industry
culminating as senior vice
president and global head for
life sciences transactions at
Bayer AG. While at Bayer, he
Gunnar
oversaw venture investments
Weikert, M.D., Director
in technology companies and
Ph.D., MBA
collaborations representing
some of the largest
transactions involving large
pharmaceutical and
biotechnology companies in the
late 1990s. Dr. Weikert
received his M.D. from the
University of Düsseldorf and his
Ph.D. in the field of metabolism
from the Diabetes Research
Center in Germany. He also
holds an MBA.
Thomas Director Dr. Werner was elected as an
Werner, Ph.D. independent director to the
Board of Directors in March,
2009. Since 2001, Dr. Werner
has been a managing director
and senior vice president of
GlaxoSmithKline (GSK) and has
served as CEO of the GSK
Foundation until earlier this
year. He led the
Pharmaceutical Research
Manufacturers of America
(PhRMA) in Germany as its
www.pharmasri.com
chairman through November
2008. He began his
pharmaceutical career with
Squibb Pharma Germany where
he held sales, marketing and
brand management positions
from 1983-1989 and later held
executive management
positions at Bristol-Myers
Squibb, including Managing
Director for Convatec Germany
and Bristol Arzneimittel
Oncology. Dr. Werner co-
founded the Genetic Research
Center, a joint venture with the
Max Planck Institute for
Psychiatry and the Ludwig-
Maximilians-University, both in
Munich. He is a member of the
Board of Trustees of the Paul
Ehrlich Association and the
Robert Koch Foundation. Dr.
Werner earned his Ph.D. in
chemistry at the University of
Göttingen in Germany.
Steven H. Advisory Dr. Steven H. Ferris is
Ferris, Ph.D. Chairman of the Accera Clinical
Advisory Board, a Gerald &
Dorothy Friedman Professor of
the New York University
Alzheimer's Disease Center,
and Executive Director of the
Silberstein Institute for Aging
and Dementia at the NYU
School of Medicine. In this
capacity he leads a staff of 30
persons that have conducted
more than 40 sponsored
clinical drug trials in aging and
Alzheimer's disease (AD). Dr.
Ferris is a recognized leader in
www.pharmasri.com
the development of
neuropsychometric tests for
memory and cognition that are
used worldwide for clinical
testing of AD drugs and
approval by regulatory
agencies. During his
distinguished career he has
authored more than 175
scientific publications and
served on the editorial boards
of numerous journals on aging
and dementia. Dr. Ferris was
awarded a Ph.D. in
Experimental Psychology by
City University of New York.
Martin R. Advisory Dr. Martin R. Farlow is Vice
Farlow, M.D. Chairman of Research and
Professor in Neurology at the
Indiana University School of
Medicine, and Director of the
Clinical Core of the Alzheimer's
Disease Clinic. His clinical
research focuses primarily on
Alzheimer's disease,
therapeutic treatments for
various dementias, and
effective diagnosis of memory
and cognitive loss secondary to
Alzheimer's disease. Dr. Farlow
has conducted greater than
100 clinical trials in Alzheimer's
disease and other dementias.
He is a highly regarded lecturer
on the treatment and care of
patients with Alzheimer's
disease. His research has led to
more than 250 publications and
he currently serves on the
editorial boards of numerous
journals related to aging,
www.pharmasri.com
dementia and research. Dr.
Farlow received his medical
education at Indiana
University.
Dr. Leif Hertz is Professor
Emeritus in the Department of
Pharmacology at University of
Saskatchewan. He is an expert
on energy metabolism in the
brain, neuronal-astrocytic
interactions and the
biochemical characteristics of
memory formation. Dr. Hertz
has more than 320 scientific
publications and has served on
Leif Hertz, the editorial boards of five
Advisory
M.D., D.Sc. prestigious journals of
neuroscience. He has held
continuous grants from the
Medical Research Council of
Canada and has received
numerous awards for his
achievements in
neurochemistry research. Dr.
Hertz received his M.D. from
University of Copenhagen and
D.Sc. from University of
Odense.
PATENTS GRANTED
Sno Patent Title

Use of medium chain triglycerides for the treatment and prevention of
1 6,835,750 alzheimer's disease and other diseases resulting from reduced neuronal
metabolism II
PATENTS APPLIED
www.pharmasri.com
Patent Appl
Sno Title
Number
Method to Reduce Oxidative Damage and Improve Mitochondrial
1 20100041751
Efficiency
2 20100003730 Enzymatic Synthesis of Acetoacetate Esters and Derivatives
Use of Ketogenic Compounds for Treatment of Age-Associated Memory
3 20080287372
Impairment
COMBINATIONS OF MEDIUM CHAIN TRIGLYCERIDES AND THERAPEUTIC
AGENTS FOR THE TREATMENT AND PREVENTION OF ALZHEIMERS
4 20080009467
DISEASE AND OTHER DISEASES RESULTING FROM REDUCED
NEURONAL METABOLISM
COMPOSITIONS AND METHODS FOR IMPROVING OR PRESERVING
5 20070179197
BRAIN FUNCTION
METHOD TO REDUCE OXIDATIVE DAMAGE AND IMPROVE
6 20070135376
MITOCHONDRIAL EFFICIENCY
Drug targets for alzheimer's disease and other diseases associated with
7 20030059824
decreased neuronal metabolism
Contact us at info@pharmasri.com

Accera

Uploaded by

Document Information

Original Description:

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Accera

Uploaded by

Copyright:

Available Formats

Pharmasri—We can provide Company reports, each will be only US$10 only.

Address Interlocken Advanced Technology Park

President and CEO Steve Orndorff, Ph.D.

Partenering details Accera is currently seeking partners to commercialize

Seeking business relationships that are collaborative and

Partnering Contat Eric Schauble mail:eschauble@accerapharma.com

Name Position mail Summary

Sno Patent Title

You might also like